Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in advanced HCC with Child-Pugh B cirrhosis
NCT04497038Phase 2Terminated
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Aug 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cabozantinib in hepatocellular carcinoma (HCC), sponsored by University of Michigan Rogel Cancer Center. Started Aug 2021; status: terminated.
02
Drugs
cabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04497038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497038.